Prospective epidemiological study of the prevalence of human leukocyte antigen (HLA)-B*5701 in HIV-1-infected UK subjects.
OBJECTIVE
Human leukocyte antigen (HLA)-B(*)5701 is strongly associated with developing a hypersensitivity reaction to abacavir (ABC) in White and Hispanic subjects. Across the UK, limited data exist on HLA-B(*)5701 prevalence in HIV-1-infected subjects. We determined HLA-B(*)5701 prevalence in the general HIV-1-infected population and in specific ethnic groups, particularly Black Africans who, in general, exhibit greater genetic diversity. We also compared HLA-B(*)5701 results obtained from local laboratories with those from a central provider.


METHODS
Multi-centre, observational study. All HIV-1-infected adult individuals receiving care at participating centres were eligible, irrespective of treatment status or prior exposure to ABC. Subjects provided samples for HLA-B(*)5701 assessment by both local (blood) and central laboratories (buccal swabs). HLA-B(*)5701 prevalence was adjusted to represent the ethnic group composition of the general UK population, and by main ethnic group. RESULTS; From eight UK centres, 1494 subjects [618 (41%) White, 770 (52%) Black] were recruited. Eighty-nine per cent of Black subjects reported an immediate country of origin in Africa. Overall adjusted HLA-B(*)5701 prevalence was 4.55% [95% confidence interval (CI) 3.49% to 5.60%]. Among White subjects, prevalence was 7.93% (CI 5.80% to 10.06%). Among Black subjects, only two (both Ugandan) were HLA-B(*)5701 positive giving a rate of 0.26% (CI 0.07% to 0.94%).


CONCLUSIONS
HLA-B(*)5701 prevalence was similar to previously reported rates in White HIV-infected subjects but considerably lower than that reported in Black HIV-1-infected subjects, as a result of the large proportion of Black African subjects.
Department of Infection and Immunity, Barts & the London NHS Trust, London, UK.
C
C
Orkin
S T
ST
Sadiq
L
L
Rice
F
F
Jackson
D000328:Adult; D000349:Africa / Q000208:ethnology; D000368:Aged; D019380:Anti-HIV Agents / Q000009:adverse effects; D044383:Black People / Q000235:genetics; D015224:Dideoxynucleosides / Q000009:adverse effects; D004342:Drug Hypersensitivity / Q000453:epidemiology / Q000235:genetics*; D016021:Epidemiologic Studies; D005260:Female; D005819:Genetic Markers; D005820:Genetic Testing / Q000379:methods; D005838:Genotype; D015658:HIV Infections / Q000188:drug therapy / Q000276:immunology*; D015235:HLA-B Antigens / Q000032:analysis* / Q000235:genetics; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D006113:United Kingdom / Q000453:epidemiology; D044465:White People; D055815:Young Adult; D000099227:Abacavir
D019380:Anti-HIV Agents; D015224:Dideoxynucleosides; D005819:Genetic Markers; D015235:HLA-B Antigens; D000099227:Abacavir; C484830:HLA-B*57:01 antigen